ClinConnect ClinConnect Logo
Search / Trial NCT00215605

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Launched by EXELIXIS · Sep 20, 2005

Trial Information

Current as of July 24, 2025

Completed

Keywords

Advanced Malignancies Solid Tumor Medullary Thyroid Cancer

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
  • Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
  • Life expectancy greater than 3 months
  • Adequate organ and marrow function
  • Written informed consent
  • Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
  • In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST
  • Exclusion Criteria:
  • Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
  • Administration of an investigational drug within 30 days of the first dose of XL184
  • Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
  • Known brain metastases
  • Uncontrolled intercurrent illness
  • Pregnancy or breastfeeding
  • Known HIV positive
  • Known allergy or hypersensitivity to any of the components of the XL184 formulation

About Exelixis

Exelixis, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. With a commitment to advancing precision medicine, Exelixis leverages its expertise in small molecule drug discovery to address unmet medical needs in oncology. The company's robust pipeline includes a range of investigational compounds targeting various cancer types, supported by rigorous clinical trials that aim to improve patient outcomes. Through collaboration and a patient-centric approach, Exelixis strives to deliver transformative therapies that enhance the quality of life for those affected by cancer.

Locations

Baltimore, Maryland, United States

Chicago, Illinois, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Baltimore, Maryland, United States

Houston, Texas, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials